The Lancet Gastroenterology & Hepatology in conversation with
Hugh Thomas, Deputy Editor at The Lancet Gastroenterology & Hepatology, in conversation with the journal’s authors, explores their latest research and its impact on people’s health, healthcare, and health policy.
A monthly audio companion to the journal, this podcast covers a broad range of topics, from predicting clinical outcomes in NAFLD to immunosuppressant withdrawal in patients with Crohn’s disease, the primary antibiotic resistance of Helicobacter pylori to surgical versus non-surgical management of malignant bowel obstruction, and more.
Podcasting since 2016 • 86 episodes
The Lancet Gastroenterology & Hepatology in conversation with
Latest Episodes
Salvatore Piano on the global epidemiology of acute kidney injury in hospitalised patients with decompensated cirrhosis
How does acute kidney injury presentation and management differ globally for patients hospitalised with cirrhosis? We spoke to Salvatore Piano, corresponding author of the landmark International Club of Ascites GLOBAL AKI study, abo...
•
19:05
John Chia on the ASCOLT trial of adjuvant aspirin for colorectal cancer
John Chia discusses the results of the ASCOLT trial, which explored the effect of aspirin after completion of standard adjuvant therapy for patients with colorectal cancer.Read the full article:
•
13:29
Hannes Hagström on screening for advanced liver fibrosis alongside retina scanning in people with type 2 diabetes
Hannes Hagström discusses a study investigating the feasibility of screening for advanced liver fibrosis alongside retina scanning in people with type 2 diabetes.Read the full article:
•
21:23
Cathy Lu on intestinal ultrasound for assessing and monitoring Crohn's disease small bowel strictures
Cathy Lu (University of Calgary) discusses a consensus statement on the use of intestinal ultrasound for assessing and monitoring small bowel strictures in Crohn's disease.Read the full article:
•
11:15
Peter De Cruz on the PREDICT-UC trial of intensified versus standard dose infliximab for steroid-refractory acute severe ulcerative colitis
Peter De Cruz (University of Melbourne) discusses the PREDICT-UC trial of intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis.Read the full article:
•
14:42